Emergent BioSolutions 8-K: Officer Changes & Disclosure

Ticker: EBS · Form: 8-K · Filed: Feb 21, 2024 · CIK: 1367644

Emergent Biosolutions Inc. 8-K Filing Summary
FieldDetail
CompanyEmergent Biosolutions Inc. (EBS)
Form Type8-K
Filed DateFeb 21, 2024
Risk Levelmedium
Pages4
Reading Time5 min
Key Dollar Amounts$0.001, $1,000,000, $8,000,000
Sentimentneutral

Sentiment: neutral

Topics: executive-changes, regulation-fd, compensatory-arrangements

TL;DR

**Emergent BioSolutions just filed an 8-K about executive changes and disclosures, so keep an eye out for details on who's in/out and any new compensation.**

AI Summary

Emergent BioSolutions Inc. filed an 8-K on February 21, 2024, reporting an event that occurred on February 20, 2024. The filing pertains to Item 5.02, "Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers," and Item 7.01, "Regulation FD Disclosure." The company, based in Gaithersburg, Maryland, operates under the pharmaceutical preparations industry.

Why It Matters

This filing indicates potential changes in leadership or executive compensation at Emergent BioSolutions, which could impact the company's strategic direction and financial performance.

Risk Assessment

Risk Level: medium — Changes in executive leadership or compensation can introduce uncertainty regarding future company strategy and stability.

Key Players & Entities

  • Emergent BioSolutions Inc. (company) — Registrant
  • February 20, 2024 (date) — Date of earliest event reported
  • February 21, 2024 (date) — Filing date
  • Gaithersburg, Maryland (company) — Principal executive offices location
  • 001-33137 (company) — Commission File Number

FAQ

What is the primary purpose of this 8-K filing by Emergent BioSolutions Inc.?

The primary purpose of this 8-K filing is to report on Item 5.02, "Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers," and Item 7.01, "Regulation FD Disclosure."

When was the earliest event reported in this 8-K filing?

The earliest event reported in this 8-K filing occurred on February 20, 2024.

What is the full name of the registrant company?

The full name of the registrant company is Emergent BioSolutions Inc.

What is the business address of Emergent BioSolutions Inc.?

The business address of Emergent BioSolutions Inc. is 400 Professional Drive, Suite 400, Gaithersburg, Maryland 20879.

What is the Commission File Number for Emergent BioSolutions Inc.?

The Commission File Number for Emergent BioSolutions Inc. is 001-33137.

Filing Stats: 1,324 words · 5 min read · ~4 pages · Grade level 10 · Accepted 2024-02-21 07:25:51

Key Financial Figures

  • $0.001 — ich registered Common Stock, Par Value $0.001 per share EBS New York Stock Exchange
  • $1,000,000 — a will receive an annual base salary of $1,000,000 (the "Annual Base Salary") and will be
  • $8,000,000 — rmance-based incentive payment equal to $8,000,000, subject to the satisfaction of a share

Filing Documents

01 Regulation FD Disclosure

Item 7.01 Regulation FD Disclosure. On February 21, 2024, the Company issued a press release announcing the Company's Chief Executive Officer transition. A copy of the press release is furnished as Exhibit 99.1 to this Current Report on Form 8-K. The information contained in this Item 7.01 shall not be deemed "filed" for the purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the "Exchange Act"), or incorporated by reference in any filing, under the Securities Act of 1933, as amended, or the Exchange Act, except as shall be expressly set forth by specific reference in such a filing.

01 Financial Statements and Exhibits

Item 9.01 Financial Statements and Exhibits. (d) Exhibits . Exhibit No. Description 10.1 Executive Agreement, dated February 19, 2024 between Emergent BioSolutions Inc. And Joseph Papa. 99.1 Press release issued by Emergent BioSolutions Inc. on February 21, 2024 104 Cover Page Interactive Data File (embedded within the Inline XBRL document).

SIGNATURES

SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. EMERGENT BIOSOLUTIONS INC. Dated: February 21, 2024 By: /s/ RICHARD S. LINDAHL Name: Richard S. Lindahl Title: Executive Vice President, Chief Financial Officer and Treasurer

View Full Filing

View this 8-K filing on SEC EDGAR

View on ReadTheFiling | About | Contact | Privacy | Terms

Data from SEC EDGAR. Not affiliated with the SEC. Not investment advice. © 2026 OpenDataHQ.